Showing 1931-1940 of 2038 results for "".
- Myopia Management Focus of Pipeline Expansion for Leo Lens Pharmahttps://modernod.com/news/myopia-management-focus-of-pipeline-expansion-for-leo-lens-pharma/2477307/Leo Lens Pharma (formerly DBA as Leo Lens Technology Co.) announced it received a notice of allowance from the United States Patent and Trademark Office for a patent for the use of its proprietary MediPrint process to manufacture a contact lens capable of providing enhance
- Gyroscope Therapeutics Strengthens Senior Leadership Ahead of Next Stage of Company Growthhttps://modernod.com/news/gyroscope-therapeutics-strengthens-senior-leadership-ahead-of-next-stage-of-company-growth/2477297/Gyroscope Therapeutics announced the strengthening of its leadership team with the hiring of Nadia Waheed, MD, MPH, from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO), and the promotion of Jane Hughes, PhD, formerly VP Translational Research, to Chief Scientific Off
- Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)https://modernod.com/news/oculis-announces-positive-ocs-01-phase-2-data-in-patients-with-diabetic-macular-edema-dme/2477287/Oculis reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment of diabetic macular edema (DME), according to a company news release. OCS-01 was developed using Oculis’ proprietary Soluble NanoParticle technolog
- Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-selects-agc-biologics-as-lead-manufacturer-of-tthx1114-for-treatment-of-corneal-diseases/2477274/AGC Biologics, a global Contract Development and Manufacturing Organization for Biopharmaceuticals, and Trefoil Therapeutics announce the execution of a manufacturing contract to supply their lead compound, TTHX1114. Trefoil is developing products based on this engineered form of FGF-1 to restore
- FDA Approves First Treatment for Thyroid Eye Diseasehttps://modernod.com/news/fda-approves-first-treatment-for-thyroid-eye-disease/2477247/The FDA approved Horizon Therapeutics’ Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease (TED), a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). The appro
- Mojo Vision Developing Smart Contact Lenshttps://modernod.com/news/mojo-vision-developing-smart-contact-lens/2477237/Mojo Vision announced it is building what it calls the “world’s first true smart contact lens,” called the Mojo Lens. Mojo Lens is a contact lens with a built-in display that gives people useful and timely information without forcing them to look down at a screen or losing focus on th
- Genentech/Roche Initiate First Diabetic Macular Edema Phase 3 Trial of the Port Delivery System with Ranibizumabhttps://modernod.com/news/genentech-roche-initiate-first-diabetic-macular-edema-phase-3-trial-of-the-port-delivery-system-with-ranibizumab/2477233/Genentech and Roche have initiated a new phase 3 clinical trial investigating the Port Delivery System with ranibizumab (PDS) in people with diabetic macular edema (DME). The PDS is an investigational first-of-its-kind refillable eye implant designed to continuously release a customized formulati
- Improved Reimbursement for Endoscopic Cyclophotocoagulation (ECP) when Combined with Cataract Surgeryhttps://modernod.com/news/improved-reimbursement-for-endoscopic-cyclophotocoagulation-ecp-when-combined-with-cataract-surgery/2477219/Beaver-Visitec International (BVI) expressed support for two new CPT codes and improved reimbursement for ECP when combined with cataract surgery. Up to 1 in 5 patients [1] undergoing cataract extraction suffers from glaucoma, and ECP remains an important option for ophtha
- Aerpio Pharmaceutical’s AKB-9778 Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandinhttps://modernod.com/news/aerpio-pharmaceuticals-akb-9778-produced-iop-lowering-with-minimal-hyperemia-when-combined-with-prostaglandin/2477211/Aerpio Pharmaceuticals announced new results from the fifth cohort of subjects from a phase 1b trial of a topical ocular formulation of AKB-9778 providing evidence of tolerability and IOP reduction from patients in that cohort with ocular hypertension (OHT) or primary open angle glaucoma (POAG).<
- NIH Launches First U.S. Clinical Trial of Patient-Derived Stem Cell Therapy to Replace Dying Cells in Retinahttps://modernod.com/news/nih-launches-first-u-s-clinical-trial-of-patient-derived-stem-cell-therapy-to-replace-dying-cells-in-retina/2477175/Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD). Geographic atrophy currently has no treatment.